HC Wainwright Has Weak Forecast for Femasys FY2024 Earnings

Femasys Inc. (NASDAQ:FEMY) – Equities researchers at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for Femasys in a research report issued on Tuesday, November 12th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.84) for the year, down from their prior forecast of ($0.78). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Femasys’ Q4 2024 earnings at ($0.22) EPS, FY2025 earnings at ($0.42) EPS, FY2026 earnings at ($0.23) EPS, FY2027 earnings at ($0.19) EPS and FY2028 earnings at ($0.04) EPS.

Femasys (NASDAQ:FEMY) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The business had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million.

Separately, Chardan Capital dropped their price target on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday.

Femasys Stock Performance

FEMY opened at $0.98 on Friday. Femasys has a 12-month low of $0.73 and a 12-month high of $2.40. The stock has a market cap of $22.44 million, a price-to-earnings ratio of -1.21 and a beta of -2.83. The business has a 50 day moving average of $1.16 and a 200-day moving average of $1.15. The company has a quick ratio of 5.93, a current ratio of 3.94 and a debt-to-equity ratio of 0.86.

Hedge Funds Weigh In On Femasys

A hedge fund recently bought a new stake in Femasys stock. Aljian Capital Management LLC acquired a new position in shares of Femasys Inc. (NASDAQ:FEMY) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 24,768 shares of the company’s stock, valued at approximately $27,000. Aljian Capital Management LLC owned about 0.11% of Femasys as of its most recent SEC filing. 65.27% of the stock is owned by institutional investors.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.